Cocrystal Pharma, Inc.
COCP
$1.31
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 12.54M | 14.77M | 15.72M | 14.21M | 15.17M |
| Gross Profit | -12.54M | -14.77M | -15.72M | -14.21M | -15.17M |
| SG&A Expenses | 5.34M | 5.55M | 5.60M | 5.99M | 5.99M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.88M | 20.31M | 21.32M | 20.21M | 21.16M |
| Operating Income | -17.88M | -20.31M | -21.32M | -20.21M | -21.16M |
| Income Before Tax | -17.50M | -18.70M | -17.93M | -16.75M | -17.98M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.50 | -18.70 | -17.93 | -16.75 | -17.98 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.50M | -18.70M | -17.93M | -16.75M | -17.98M |
| EBIT | -17.88M | -20.31M | -21.32M | -20.21M | -21.16M |
| EBITDA | -17.75M | -20.18M | -21.15M | -20.03M | -20.97M |
| EPS Basic | -1.72 | -1.84 | -1.76 | -1.65 | -1.90 |
| Normalized Basic EPS | -1.08 | -1.21 | -1.26 | -1.19 | -1.35 |
| EPS Diluted | -1.72 | -1.84 | -1.76 | -1.65 | -1.90 |
| Normalized Diluted EPS | -1.08 | -1.21 | -1.26 | -1.19 | -1.35 |
| Average Basic Shares Outstanding | 40.70M | 40.74M | 40.72M | 40.61M | 38.58M |
| Average Diluted Shares Outstanding | 40.70M | 40.74M | 40.72M | 40.61M | 38.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |